

Yoo Jin Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1967668/publications.pdf>

Version: 2024-02-01

46
papers

310
citations

1040056

9
h-index

940533

16
g-index

48
all docs

48
docs citations

48
times ranked

652
citing authors

#	ARTICLE	IF	CITATIONS
1	Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. <i>Blood</i> , 2018, 132, 1604-1613.	1.4	84
2	Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2021, 29, 975-986.	2.2	20
3	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <i>Oncotarget</i> , 2018, 9, 4961-4968.	1.8	19
4	Clinical significance of nuclear factor κ B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 785.	1.7	17
5	Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate. <i>International Journal of Hematology</i> , 2013, 97, 804-807.	1.6	14
6	BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. <i>Haematologica</i> , 2017, 102, e187-e190.	3.5	13
7	Updated recommendations for the treatment of venous thromboembolism. <i>Blood Research</i> , 2021, 56, 6-16.	1.3	11
8	A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea. <i>Cancer Medicine</i> , 2018, 7, 1814-1823.	2.8	10
9	Clinical Utility of 18F-Florbetaben PET for Detecting Amyloidosis Associated With Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2019, 44, e503-e509.	1.3	10
10	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	6.2	10
11	Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. <i>Leukemia Research</i> , 2016, 49, 80-87.	0.8	9
12	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019, 109, 79-90.	1.6	9
13	Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death. <i>BMC Cancer</i> , 2020, 20, 1193.	2.6	8
14	Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act. <i>BMC Palliative Care</i> , 2021, 20, 63.	1.8	8
15	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. <i>Scientific Reports</i> , 2020, 10, 20119.	3.3	6
16	Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. <i>Annals of Hematology</i> , 2021, 100, 2051-2059.	1.8	6
17	Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. <i>Leukemia Research</i> , 2018, 69, 31-38.	0.8	5
18	The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway. <i>Scientific Reports</i> , 2021, 11, 13198.	3.3	5

#	ARTICLE	IF	CITATIONS
19	Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts. <i>Annals of Hematology</i> , 2018, 97, 2309-2317.	1.8	4
20	Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study. <i>In Vivo</i> , 2019, 33, 2273-2280.	1.3	4
21	Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14199.	1.6	4
22	LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells. <i>PLoS ONE</i> , 2021, 16, e0247368.	2.5	4
23	Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling. <i>PLoS ONE</i> , 2022, 17, e0265958.	2.5	4
24	Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML. <i>Chonnam Medical Journal</i> , 2011, 47, 80.	0.9	3
25	Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. <i>European Journal of Haematology</i> , 2020, 105, 262-273.	2.2	3
26	New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 435-437.	1.7	3
27	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2051-2059.	2.4	2
28	Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). <i>Bone Marrow Transplantation</i> , 2020, 55, 1466-1468.	2.4	2
29	Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. <i>Annals of Hematology</i> , 2021, 100, 189-196.	1.8	2
30	Genetic variations in miRNA binding site of <i>TPST1</i> and <i>ZG16B</i> associated with prognosis for patients with colorectal cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3553-3553.	1.6	2
31	Phosphorylated AMP-activated protein kinase and MAPK3/1 expression associated with prognosis for patients with gastric cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 36-36.	1.6	2
32	Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia. <i>Blood Research</i> , 2016, 51, 44.	1.3	1
33	Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2016, 95, 1795-1804.	1.8	1
34	Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e367-e373.	0.4	1
35	Impact of ATG on New HLA Groups for Unrelated Donor Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 3017-3017.	1.4	1
36	No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 1194-1202.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Different Immunohistochemical Localization of Fatty Acid Binding Protein 5 in Actinic Keratosis Compared with That in Bowen's Disease: A Retrospective Study. <i>American Journal of Dermatopathology</i> , 2021, 43, 356-361.	0.6	1
38	Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e529-e535.	0.4	0
39	Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity. <i>Blood Research</i> , 2021, 56, 102-108.	1.3	0
40	Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML. <i>Blood</i> , 2010, 116, 2272-2272.	1.4	0
41	Clinical significance of nuclear kappa B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18533-e18533.	1.6	0
42	Impact of ATG on new HLA groups for unrelated donor allogeneic stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6536-6536.	1.6	0
43	AQP5 variant associated with prognosis in patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11505-e11505.	1.6	0
44	Functional polymorphism in the microRNA-367 binding site as a prognostic factor for colonic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14549-e14549.	1.6	0
45	Association of expression of aquaporin 5 (AQP5) with prognosis in hormone-responsive early breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11594-e11594.	1.6	0
46	Impact of antithymocyte globulin on new HLA groups for unrelated donor allogeneic stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2013, 31, e18017-e18017.	1.6	0